Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ASPE returns to Louisiana

Executive Summary

HHS Deputy Assistant Secretary for Planning & Evaluation William Raub will be acting assistant secretary during search for a replacement for Bobby Jindal. The former executive director of the bipartisan Medicare commission has decided to return to Louisiana where he is contemplating a run for governor. Jindal is the second HHS assistant secretary to leave this year, following Assistant Secretary for Health Eve Slater (1"The Pink Sheet" Feb. 10, p. 10). Jindal was one of the key advisors on Medicare prescription drug proposals in the Administration; the White House has backed away from providing a detailed legislative proposal for 2003...

You may also be interested in...

President nominates HHS assistant secretaries

President Bush nominates HHS Principal Deputy Assistant Secretary Cristina Beato to be assistant secretary for health July 23. Beato would replace U.S. Surgeon General Richard Carmona, MD, who has been acting assistant secretary since Eve Slater, MD, resigned in February ("The Pink Sheet" Feb. 10, 2003, p. 10). Administration also names Senate Joint Economic Committee Senior Health Economist Michael O'Grady, PhD, to be HHS assistant secretary for planning & evaluation. O'Grady would replace former ASPE Bobby Jindal (1"The Pink Sheet" Feb. 17, 2003, In Brief)...

FDA To Ramp Up ASCA Pilot In 2021

A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.

Scotland's MGB Plots Phase III For Promising Antibacterial

With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts